
Cell X Technologies is pioneering a revolution in cell processing with its Celligent™ platform, which integrates robotics, imaging, and artificial intelligence to enable consistent, reproducible, and scalable GMP-compliant processes for cellular therapies, stem cell-derived therapies, tissue engineering, and artificial organs. The platform automates critical early-stage cell handling to reduce human error and contamination, employs machine learning to continuously improve processes, and collects robust data to support regulatory filings. This innovative approach facilitates the commercialization of autologous and allogeneic cell therapies, enhancing safety, efficacy, and manufacturing reliability, positioning Cell X as a leader in advanced cell therapy manufacturing technology.

Cell X Technologies is pioneering a revolution in cell processing with its Celligent™ platform, which integrates robotics, imaging, and artificial intelligence to enable consistent, reproducible, and scalable GMP-compliant processes for cellular therapies, stem cell-derived therapies, tissue engineering, and artificial organs. The platform automates critical early-stage cell handling to reduce human error and contamination, employs machine learning to continuously improve processes, and collects robust data to support regulatory filings. This innovative approach facilitates the commercialization of autologous and allogeneic cell therapies, enhancing safety, efficacy, and manufacturing reliability, positioning Cell X as a leader in advanced cell therapy manufacturing technology.
Product: Celligent™ platform — robotics, imaging, and AI for automated GMP‑compliant cell processing
Use cases: Autologous/allogeneic cell therapies, stem cell‑derived therapies, tissue engineering, artificial organs
Founded: 2019
Headquarters: Cleveland, Ohio
Recent funding: Seed round announced Aug 1, 2024
Improving reproducibility, scalability, and regulatory readiness in cell therapy and tissue‑engineering manufacturing.
2019
Biotechnology
Seed round announced Aug 1, 2024; investors/supporters include Innovation Works and The Robotics Factory
“Innovation Works, The Robotics Factory”